Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
复制标题
DOI：
10.1111/bjh.18138
复制
发表时间：
2022-06
影响因子：
6.5
通讯作者：
Kondo, Takeshi
中科院分区：
文献类型：
--
作者：
Mori, Akio;Onozawa, Masahiro;Tsukamoto, Shihori;Ishio, Takashi;Yokoyama, Emi;Izumiyama, Koh;Saito, Makoto;Muraki, Haruna;Morioka, Masanobu;Teshima, Takanori;Kondo, Takeshi
关于髓系恶性肿瘤患者对新冠肺炎疫苗的反应的数据尚未出现，这些患者在感染后面临严重风险。对69例髓系恶性肿瘤患者，包括46例急性髓系白血病(AML)和23例骨髓增生异常综合征(MDS)患者，在第二次以mRNA为基础的疫苗接种后3个月检测抗SARS-CoV-2抗体滴度。AML和MDS患者的血清阳转率分别为94.7%和100%，与健康对照组(HCS)比较差异无统计学意义。MDS患者的抗体滴度明显低于HCS和AML患者。在AML患者中，治疗结束时抗体滴度与HCS患者相当，但在接受维持治疗的患者中较低。对新冠肺炎疫苗的反应似乎与疾病和治疗状态有关。髓系恶性肿瘤患者可能比淋巴系恶性肿瘤患者对疫苗更敏感。
Data on the response to the COVID‐19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome (MDS), anti‐spike SARS‐CoV‐2 antibody titres were measured 3 months after the second mRNA‐based vaccination. Seroconversion rates for AML and MDS were 94.7% and 100% respectively, with no significant difference from healthy controls (HCs). Patients with MDS showed a significantly lower antibody titre than that in HCs or AML patients. In AML patients, the antibody titres were comparable to those in HCs when treatment was completed, but lower in patients under maintenance therapy. The response to COVID‐19 vaccine appears to be related to disease and treatment status. Patients with myeloid malignancies may be more responsive to vaccines than patients with lymphoid malignancies.
登录
查看更多内容
影响因子：
11.8
作者：
Cordonnier, Catherine;Ljungman, Per;Schmoele-Thoma, Beate
通讯作者：
Schmoele-Thoma, Beate
影响因子：
6.5
作者：
Benda, Magdalena;Mutschlechner, Beatrix;Winder, Thomas
通讯作者：
Winder, Thomas
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2107659
发表时间：
2021-09-23
期刊：
The New England journal of medicine
影响因子：
--
作者：
Heath PT;Galiza EP;Baxter DN;Boffito M;Browne D;Burns F;Chadwick DR;Clark R;Cosgrove C;Galloway J;Goodman AL;Heer A;Higham A;Iyengar S;Jamal A;Jeanes C;Kalra PA;Kyriakidou C;McAuley DF;Meyrick A;Minassian AM;Minton J;Moore P;Munsoor I;Nicholls H;Osanlou O;Packham J;Pretswell CH;San Francisco Ramos A;Saralaya D;Sheridan RP;Smith R;Soiza RL;Swift PA;Thomson EC;Turner J;Viljoen ME;Albert G;Cho I;Dubovsky F;Glenn G;Rivers J;Robertson A;Smith K;Toback S;2019nCoV-302 Study Group
通讯作者：
2019nCoV-302 Study Group
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y